Ignite Creation Date:
2024-05-06 @ 9:01 AM
Last Modification Date:
2024-10-26 @ 12:08 PM
Study NCT ID:
NCT02881762
Status:
COMPLETED
Last Update Posted:
2024-05-01
First Post:
2016-08-10
Brief Title:
Maraviroc Efficacy for Hepatitis C
Sponsor:
University of Maryland Baltimore
Organization:
University of Maryland Baltimore
Study Overview
Official Title:
A Pilot Study to Evaluate Anti-Hepatitis C Virus Effect of Maraviroc in Patients Co-infected With Human Immunodeficiency Virus HIV and Hepatitis C
Status:
COMPLETED
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MAVERIC
Brief Summary:
This is a single-site longitudinal open-label interventional study for evaluating the effect of maraviroc on hepatitis C viral levels in patients infected with both hepatitis C and human immunodeficiency virus HIV and taking antiretroviral therapy for HIV
Detailed Description:
Recently in-vitro studies experiments performed in a laboratory not on a person have demonstrated that maraviroc a medication that is used in human immunodeficiency HIV therapy appears to have significant hepatitis C antiviral effect comparable to sofosbuvir-a potent anti-hepatitis C medication In this study the investigators will evaluate the antiviral effect of maraviroc on hepatitis C virus in people infected with both hepatitis C and HIV and whom have never been treated for hepatitis with direct antiviral agents Participants will take maraviroc for 4 weeks in addition to their regular HIV antiretrovirals ART The investigators will measure the hepatitis C viral load before during and after the 4-week maraviroc time
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None